Please login to the form below
Dr Reddy's Laboratories
This page shows the latest Dr Reddy's Laboratories news and features for those working in and with pharma, biotech and healthcare.
Amarin shares tumble following Vascepa patent loss
Dr Reddy’s Laboratories and Hikma Pharmaceuticals are already queueing up to launch generic versions of Vascepa, with Hikma reporting that it is working with the FDA to gain approval for ... The patent ruling only applies to Vascepa’s US patent
Latest news
-
GSK and Apotex join generic Zantac recalls as carcinogen concerns mount
Reddy’s Laboratories and Saraca Laboratories. A spokeswoman for GSK, Kristen Neese, reportedly said in an email that Dr. ... Reddy’s has an FDA-approval to sell its own versions of prescription and OTC generic Zantac in the US.
-
Indivior push to diversify boosted by schizophrenia drug approval
The two approvals come as Indivior is fighting a rearguard action to protect Suboxone from a generic developed by Dr Reddy’s Laboratories. ... Reddy’s generic earlier this month.
-
Indivior slumps as patent dispute rises US generic spectre
Indivior said it plans to appeal the decision, which held that three US patents on Suboxone were valid but that a generic from Indian drugmaker Dr Reddy's Laboratories drug does ... He said that Dr Reddy's has not yet been granted FDA approval for its
-
Fresenius Kabi buys Akorn and Merck's biosimilar businesses
Adding in Merck's biosimilars business takes it right back into the biotech sphere. ... Merck kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories at a time when the company was facing patent expiries on some
-
Merck confirms sale of biosimilar division
The German group kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories, at a time when the company was facing patent expiries on ... At the time the Dr Reddy's deal was announced the biosimilars market was a
More from news
Approximately 1 fully matching, plus 37 partially matching documents found.
Latest Intelligence
-
Deal Watch June 2016
The three deals with Mayne Pharma, Impax Laboratories and Dr Reddy's, for a combined value of over $1.5bn, cover portfolios of marketed and approved generic drugs, drugs currently pending ... acquisition assets/ return of rights. 586. Teva and Allergan/
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
MedImmune appoints Dr Anand Subramony
While at Novartis Dr Subramony established and headed company's novel delivery technologies and therapeutics group. ... Prior to that he held leadership positions at Dr. Reddy's Laboratories in Bridgewater, New Jersey and Johnson &Johnson/Alza
-
New global head of HR for Dr Reddy’s
Sripada Chandrasekhar joins from IBM. Hyderabad, India-headquartered Dr Reddy's Laboratories has appointed a former IBM executive president and global head of human resources. ... Chakraborty remains with Dr Reddy's, and has retained all but the HR
-
Dr Reddy’s appoints Umang Vohra to lead US business
Will be replaced as chief financial officer by Saumen Chakraborty. Indian generics company Dr Reddy's Laboratories has appointed Umang Vohra as the new head of its North American business. ... He first joined the company in 2002, moving from Pepsico-India
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Novo Nordisk to buy Dicerna Pharmaceuticals for $3.3bn
- US demand for COVID-19 antibody treatments rising fast
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Novo Nordisk to buy Dicerna Pharmaceuticals for $3.3bn
- AstraZeneca/Moderna’s mRNA treatment for heart failure looks promising
- First trial of a vaccine against Alzheimer’s launches
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
